Study of PF-08634404 With Different Cancer Medicines in Adults With Advanced Lung Cancer

What this Trial Is About

Researchers are studying a new medicine called PF-08634404 to understand how it works when combined with other cancer medicines in people with advanced solid tumors, specifically advanced non-small cell lung cancer NSCLC that has spread and cannot be cured with surgery or standard treatments. This study is an interventional Phase 1B2 trial sponsored by Pfizer, focusing on treatment safety, side effects, and effectiveness. The trial evaluates PF-08634404 combined with different anticancer agents to explore their impact on these advanced cancers. Participants will receive PF-08634404 through intravenous IV infusion along with other cancer medicines. The study is divided into parts Part A tests PF-08634404 with Sigvotatug Vedotin, and Part B evaluates PF-08634404 with another anticancer agent. All treatments and infusions are given at clinical trial sites under medical supervision, with careful monitoring during and after each visit. During the study, participants will undergo assessments to track safety by monitoring adverse events and serious adverse events up to 90 days after the last dose and for up to approximately 5 years. Researchers will measure responses using imaging criteria RECIST v1.1 to evaluate tumor response and disease control. Additional tests include laboratory evaluations, pharmacokinetics to measure drug levels, and monitoring for immune reactions. The study duration spans several years with ongoing safety and efficacy evaluations.

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers